导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.63% | 2278/4773 |
| 近一周 | -0.73% | 1738/5491 |
| 近一月 | -2.98% | 1990/5408 |
| 近一季 | -2.47% | 2161/5202 |
| 近半年 | -0.55% | 1374/4919 |
| 近一年 | 2.91% | 2156/4356 |
| 近两年 | 46.98% | 1596/2950 |
| 近三年 | 29.59% | 1054/2241 |
| 成立以来 | 66.44% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.76% 3401/4961 |
13.05% 2073/5312 |
- - |
- - |
| 2025 | 19.79% 2180/4813 |
-0.54% 2295/3635 |
2.09% 1880/4076 |
17.87% 2413/4524 |
0.10% 2222/4813 |
| 2024 | 16.98% 744/3463 |
1.97% 837/2808 |
-0.38% 755/3014 |
17.02% 1288/3129 |
-1.59% 1763/3463 |
| 2023 | -8.35% 1003/2656 |
3.72% 1141/2280 |
-3.87% 938/2385 |
-1.85% 589/2515 |
-6.35% 1735/2655 |
| 2022 | -16.63% 496/2207 |
-12.21% 589/1919 |
7.42% 481/2016 |
-12.87% 797/2113 |
1.47% 1253/2208 |
| 2021 | 1.65% 660/1822 |
-1.43% 490/1255 |
5.52% 805/1330 |
-4.01% 674/1466 |
1.82% 790/1822 |
| 2020 | - - |
- - |
- - |
17.98% 93/1164 |
13.78% 330/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 中泰沪深300增强C VS. 长安沪深300非周期A(740101) |